Pfizer and Moderna shares rose after approval of booster dose of vaccine
An independent group should make the final decision today of experts from the Center for Control and Prevention (CDC). CDC Director Rochelle Walensky promises that the agency will “act quickly” The U.S. Food and Drug Administration (FDA) has approved booster doses of Covid-19 vaccines from Moderna (MRNA) and Pfizer (PFE) for all adult Americans.
Vaccine manufacturers – Pfizer and Moderna – grew at a maximum of 2.66% and 9.31%, respectively. Pfizer securities simultaneously updated the historical maximum, reaching $52.83 growth slowed to 1.07% and 5.74%, respectively. American depositary receipts of BioNTech at the opening of trading on the NASDAQ stock exchange rose by 4.44%; later, growth slowed to 2.17%.
The FDA noted that adults who received the second dose of the coronavirus vaccine more than six months ago have the right to make the third injection. In addition, the third dose can be from any company, regardless of which vaccine the person is with initially. “This authorization for emergency use comes at a critical time when we are entering the winter months and seeing an increase in the number of COVID-19 infections and hospitalizations across the country,” said Stefan Bansal, CEO of Moderna.
IN SEPTEMBER, the FDA advisory panel initially met to recommend Pfizer boosters but decided not to approve the additional dose due to insufficient data. However, in September, the head of the Center for Control and Prevention (CDC) approved the use of other injections from Pfizer for the elderly and people at increased risk of Covid-19.
In October, I made a similar decision on Moderna and Johnson & Johnson vaccines. Concern that the effectiveness of initial vaccinations may decrease as the cold weather sets in, as more and more people will gather indoors, has pushed for more widespread use of booster vaccinations, Bloomberg notes. Data published in the journal Science (an authoritative American scientific publication) indicate that the effectiveness of all three vaccines approved in the U.S has decreased.
Pfizer’s vaccine effectiveness decreased from 86% to 43% from February to October this year, Moderna — from 89% to 58%, and Johnson & Johnson – from 86% to 13%. However, according to scientists, vaccines still provide a high level of protection against hospitalization and death.
The CDC’s independent panel of vaccine experts is due to meet today to review the new data and decide on boosters. CDC director Rochelle Walenski said Wednesday that the agency would “act quickly” after the FDA reviews the data and gives its approval for the use of booster doses.
